• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Cullinan Therapeutics, Inc.

News headline image
Cullinan Therapeutics Receives FDA Fast Track Designation for CLN-049, a Novel FLT3xCD3 T Cell Engager, in Relapsed/Refractory Acute Myeloid Leukemia
December 01, 2025
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
Tickers CGEM
News headline image
Cullinan Therapeutics to Participate in Upcoming Investor Conferences and Host Analyst and Investor Event at 2025 ASH Annual Meeting
November 10, 2025
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
Tickers CGEM
News headline image
Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results
November 06, 2025
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
Tickers CGEM
News headline image
Cullinan Therapeutics to Showcase New Data Demonstrating Compelling Clinical Activity for CLN-049, a Novel FLT3xCD3 T Cell Engager, in AML Patients in an Oral Presentation at the 67th ASH Annual Meeting
November 03, 2025
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
Tickers CGEM
News headline image
Cullinan Therapeutics Shares Additional Preclinical B Cell Depletion Data for CLN-978, Supporting Clinical Development Across Multiple Autoimmune Diseases, at ACR Convergence 2025
October 25, 2025
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
Tickers CGEM
News headline image
Cullinan Therapeutics to Participate in Fireside Chat at the Stifel 2025 Virtual Immunology and Inflammation Forum
September 12, 2025
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
Tickers CGEM
News headline image
Cullinan Therapeutics to Participate in Upcoming Investor Conferences
August 21, 2025
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
Tickers CGEM
News headline image
Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results
August 07, 2025
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
Tickers CGEM
News headline image
Cullinan Therapeutics Licenses Rights to Velinotamig, a Clinical-Stage BCMA-Directed Bispecific T Cell Engager, from Genrix Bio for Development in Autoimmune Diseases
June 04, 2025
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
Tickers CGEM
News headline image
Cullinan Therapeutics to Host Analyst and Investor Event at 2025 ASCO Annual Meeting and Participate in Jefferies 2025 Global Healthcare Conference
May 29, 2025
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
Tickers CGEM
News headline image
Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results
May 08, 2025
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
Tickers CGEM
News headline image
Cullinan Therapeutics to Initiate Study of CLN-978, a Bispecific CD19 T Cell Engager Administered Subcutaneously, in Patients with Sjögren’s Disease in the United States
April 29, 2025
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
Tickers CGEM
News headline image
Cullinan Therapeutics to Present Results from REZILIENT1, a Phase 1/2 Trial of Zipalertinib in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who Have Received Prior Therapy, at ASCO 2025
April 23, 2025
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
Tickers CGEM
News headline image
Cullinan Therapeutics Receives Approval from European Medicines Agency to Initiate Phase 1 Trial of CLN-978, a Bispecific CD19 T Cell Engager Administered Subcutaneously, in Patients with Rheumatoid Arthritis
April 16, 2025
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
Tickers CGEM
News headline image
Cullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results
February 27, 2025
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
Tickers CGEM
News headline image
Cullinan Therapeutics to Participate in Upcoming Investor Conferences
February 24, 2025
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
Tickers CGEM
News headline image
Cullinan Therapeutics to Participate in Fireside Chat at the Guggenheim Securities SMID Cap Biotech Conference
January 30, 2025
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
Tickers CGEM
News headline image
Cullinan Therapeutics Announces Preclinical Data for CLN-978, a CD19-directed T Cell Engager, to be Presented at ACR Convergence 2024
November 14, 2024
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
Tickers CGEM
News headline image
Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
November 07, 2024
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
Tickers CGEM
News headline image
Cullinan Therapeutics to Participate in Fireside Chat at Stifel 2024 Healthcare Conference
November 05, 2024
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
Tickers CGEM
News headline image
Cullinan Therapeutics to Present Preclinical Data for CLN-978, a CD19-directed T Cell Engager, at ACR Convergence 2024
November 04, 2024
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
Tickers CGEM
News headline image
Cullinan Therapeutics Receives U.S. FDA Clearance of Investigational New Drug Application for CLN-978 Administered Subcutaneously in Patients with Moderate to Severe Systemic Lupus Erythematosus
October 16, 2024
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
Tickers CGEM
News headline image
Cullinan Therapeutics Receives Approval to Initiate its Global Phase 1 Clinical Trial of CLN-978 for the Treatment of Systemic Lupus Erythematosus
September 17, 2024
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
Tickers CGEM
News headline image
Cullinan Therapeutics Announces Submission of Investigational New Drug Application to U.S. Food and Drug Administration for CLN-978 to Treat Systemic Lupus Erythematosus
September 16, 2024
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
Tickers CGEM
News headline image
Cullinan Therapeutics Presents Positive Updated Data from Module C of Zipalertinib Pivotal Phase 2b Study at ESMO 2024
September 14, 2024
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
Tickers CGEM
News headline image
Cullinan Therapeutics to Participate in Upcoming Investor Conferences
August 28, 2024
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
Tickers CGEM
News headline image
Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results
August 08, 2024
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
Tickers CGEM
News headline image
Cullinan Therapeutics Announces Positive Initial Data from Pivotal Phase 2b REZILIENT1 Study of Zipalertinib
June 01, 2024
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
Tickers CGEM
News headline image
Cullinan Therapeutics to Participate in Fireside Chat at TD Cowen 5th Annual Oncology Innovation Summit
May 24, 2024
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
Tickers CGEM
News headline image
Cullinan Therapeutics to Present First Data for CLN-619, a Novel Anti-MICA/B Antibody, in Combination with a Checkpoint Inhibitor and Updated Monotherapy Data at ASCO 2024
May 23, 2024
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
Tickers CGEM
FinancialContent
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap